Bayer stresses drug's tolerability in bid for prostate cancer market
February 14, 2019 at 16:45 PM EST
Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.